査読有
doi：10.1016/j.cgh.2026.03.040
PubMed No.：41974245
2024 Impact Factor：12.2
種類：Research Letter
誌名：Clinical Gastroenterology and Hepatology
発行年月：2026年4月
巻号頁：in press
論題：Refining HEPAmet for treatment eligibility in MASLD: External Validation and Guardrail to Exclude Cirrhosis, Limit Early Disease
著者：Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Hideki Hayashi, Hirokazu Takahashi, Mary E Rinella; Corporation author is JSG-NAFLD Group
